Ceftazidime

(sef' tay zi deem)

PCaution when used during lactation:Caution when used during pregnancy

LCaution when used during lactation:Caution when used during lactation

Molecule Info

 | See TERMINOLOGY & ABBREVIATIONS |
Indication(s) & Dosage Pseudomonal lung infections in cystic fibrosis
Adult: 90-150 mg/kg/day in 3 divided doses via IM or IV inj or IV infusion, up to 9 g/day. Doses >1 g should be given via IV route. 
Max Dosage: 9 g daily. Doses >1 g should be administered IV.

Prophylaxis of surgical infection in patients undergoing prostate surgery
Adult: 1 g at induction of anesth repeated if necessary upon removal of catheter. 

Biliary tract infections
Adult: 1-6 g daily in divided doses every 8 or 12 hr as deep IM, slow IV Inj over 3-5 min or infusion for up to 30 min.
Child: 30-100 mg/kg/day in 2 or 3 divided doses increased up to 150 mg/kg daily in severe cases. Neonates and infants ≤2 mth: 25-60 mg/kg/day in 2 divided doses. Max dose: 6 g daily in divided doses. 
Elderly: Max dose: 3 g daily. 

Bone and joint infections
Adult: 1-6 g daily in divided doses every 8 or 12 hr as deep IM, slow IV Inj over 3-5 min or infusion for up to 30 min.
Child: 30-100 mg/kg/day in 2 or 3 divided doses increased up to 150 mg/kg daily in severe cases. Neonates and infants ≤2 mth: 25-60 mg/kg/day in 2 divided doses. Max dose: 6 g daily in divided doses. 
Elderly: Max dose: 3 g daily. 


Infections in immunocompromised patients
Adult: 1-6 g daily in divided doses every 8 or 12 hr as deep IM, slow IV Inj over 3-5 min or infusion for up to 30 min.
Child: 30-100 mg/kg/day in 2 or 3 divided doses increased up to 150 mg/kg daily in severe cases. Neonates and infants ≤2 mth: 25-60 mg/kg/day in 2 divided doses. Max dose: 6 g daily in divided doses. 
Elderly: Max dose: 3 g daily.

Meningitis
Adult: 1-6 g daily in divided doses every 8 or 12 hr as deep IM, slow IV Inj over 3-5 min or infusion for up to 30 min.
Child: 30-100 mg/kg/day in 2 or 3 divided doses increased up to 150 mg/kg daily in severe cases. Neonates and infants ≤2 mth: 25-60 mg/kg/day in 2 divided doses. Max dose: 6 g daily in divided doses. 
Elderly: Max dose: 3 g daily. 

Peritonitis
Adult: 1-6 g daily in divided doses every 8 or 12 hr as deep IM, slow IV Inj over 3-5 min or infusion for up to 30 min.
Child: 30-100 mg/kg/day in 2 or 3 divided doses increased up to 150 mg/kg daily in severe cases. Neonates and infants ≤2 mth: 25-60 mg/kg/day in 2 divided doses. Max dose: 6 g daily in divided doses. 
Elderly: Max dose: 3 g daily. 

Pneumonia
Adult: 1-6 g daily in divided doses every 8 or 12 hr as deep IM, slow IV Inj over 3-5 min or infusion for up to 30 min.
Child: 30-100 mg/kg/day in 2 or 3 divided doses increased up to 150 mg/kg daily in severe cases. Neonates and infants ≤2 mth: 25-60 mg/kg/day in 2 divided doses. Max dose: 6 g daily in divided doses. 
Elderly: Max dose: 3 g daily.

Skin infections
Adult: 1-6 g daily in divided doses every 8 or 12 hr as deep IM, slow IV Inj over 3-5 min or infusion for up to 30 min.
Child: 30-100 mg/kg/day in 2 or 3 divided doses increased up to 150 mg/kg daily in severe cases. Neonates and infants ≤2 mth: 25-60 mg/kg/day in 2 divided doses. Max dose: 6 g daily in divided doses. 
Elderly: Max dose: 3 g daily. 


Melioidosis
Adult: 1-6 g daily in divided doses every 8 or 12 hr as deep IM, slow IV Inj over 3-5 min or infusion for up to 30 min.
Child: 30-100 mg/kg/day in 2 or 3 divided doses increased up to 150 mg/kg daily in severe cases. Neonates and infants ≤2 mth: 25-60 mg/kg/day in 2 divided doses. Max dose: 6 g daily in divided doses. 
Elderly: Max dose: 3 g daily.

Upper respiratory tract infections
Adult: 1-6 g daily in divided doses every 8 or 12 hr as deep IM, slow IV Inj over 3-5 min or infusion for up to 30 min.
Child: 30-100 mg/kg/day in 2 or 3 divided doses increased up to 150 mg/kg daily in severe cases. Neonates and infants ≤2 mth: 25-60 mg/kg/day in 2 divided doses. Max dose: 6 g daily in divided doses. 
Elderly: Max dose: 3 g daily. 

Endophthalmitis
Adult: 1-6 g daily in divided doses every 8 or 12 hr as deep IM, slow IV Inj over 3-5 min or infusion for up to 30 min.
Child: 30-100 mg/kg/day in 2 or 3 divided doses increased up to 150 mg/kg daily in severe cases. Neonates and infants ≤2 mth: 25-60 mg/kg/day in 2 divided doses. Max dose: 6 g daily in divided doses. 
Elderly: Max dose: 3 g daily. 


Urinary tract infections
Adult: 1-6 g daily in divided doses every 8 or 12 hr as deep IM, slow IV Inj over 3-5 min or infusion for up to 30 min.
Child: 30-100 mg/kg/day in 2 or 3 divided doses increased up to 150 mg/kg daily in severe cases. Neonates and infants ≤2 mth: 25-60 mg/kg/day in 2 divided doses. Max dose: 6 g daily in divided doses. 
Elderly: Max dose: 3 g daily. 

Renal impairment: Loading dose: 1 g; maintenance doses based on CrCl. May need to increase doses by 50% in severe infections. Peritoneal dialysis: Loading dose is followed by 500 mg every 24 hr; may add ceftazidime to the dialysis fluid (usually 125-250 mg for 2 litres of dialysis fluid). Haemodialysis: Admin loading dose then 0.5-1 g after each dialysis period.

CrCl (ml/min) Dosage Recommendation
31-50 1 g every 12 hr.
16-30 1 g every 24 hr.
6-15 500 mg every 24 hr.
<5 500 mg every 48 hr.
Special Populations: Renal impairment: 1 g loading dose followed by a maintenance dose based on patients creatinine clearance. CrCl: 31-50 mL/min: 1 g every 12 hrs; 16-30 mL/min: 1 g every 12 hrs; 6-15 mL/min: 0.5 g every 24 hrs; <5 mL/min: 0.5 g every 48 hrs. Increase dose by 50% in severe infections. Patients undergoing peritoneal dialysis: 1 g loading dose followed by 500 mg every 24 hrs. Patients undergoing haemodialysis: 1 g loading dose repeated after each dialysis period.
Administration May be taken with or without food.
Contraindications Hypersensitivity to cephalosporins.
Special Precautions History of penicillin allergy; severe renal impairment; pregnancy, lactation.
Adverse Drug Reaction(s) Hypersensitivity, dizziness, diarrhoea, nausea, vomiting, renal impairment, rash, erythema multiforme, thrombocytopaenia, superinfection, phloebitis and thrombophloebitis at the site of injection.
Potentially Fatal: Anaphylactic reactions, nephrotoxicity, pseudomembranous colitis.
Drug Interactions Probenecid may decrease ceftazidime elimination time.
Potentially Fatal: Furosemide and aminoglycosides may increase nephrotoxicity. Please consult detailed drug interactions before prescribing.
Lab Interference False-positives for Coombs' test and urinary glucose.
Pregnancy Category (FDA) Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later trimesters).
Storage Parenteral: Store at 15-30°C.
Pharmacology Ceftazidime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Absorption: Peak plasma concentrations after 1 hr (IM), 5 min (IV bolus).
Distribution: Widely distributed in body tissues and fluids; CSF (therapeutic concentrations when meninges are inflamed). Crosses the placenta and enters breast milk. Protein-binding: 10%
Excretion: Mainly by the kidneys via the urine by glomerular filtration (80-90% as unchanged drug within 24 hr); passively excreted in bile but only a small proportion is eliminated. Clearance enhanced in cystic fibrosis; 2 hr (elimination half-life), prolonged in neonates and renal impairment.
ATC Classification J01DD02 - ceftazidime.

Brand/Product Info


Total Products : 22                      
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
CEFAZID Renata Limited Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.00, 115.43, 215.81 MRP
CEFTAZIM Aristopharma Ltd. Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 75.00, 120.00, 220.00 MRP
CEFZON Navana Pharmaceuticals Limited Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.26, 115.43, 215.80 MRP
LESERO Ziska Pharmaceuticals Ltd. Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.00, 115.00, 215.00 MRP
MAXBAC Rangs Pharmaceuticals Ltd. Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.00, 115.00, 215.00 MRP
MAXIDIM 1GM Beximco Pharmaceuticals Ltd Ceftazidime USP 1gm IV/IM Injection 1's: 240.00 MRP
MAXIDIM 250MG Beximco Pharmaceuticals Ltd Ceftazidime USP 250mg IV/IM Injection 1's: 85.00 MRP
MAXIDIM 500MG Beximco Pharmaceuticals Ltd Ceftazidime USP 500mg IV/IM Injection 1's: 130.00 MRP
SEROZID Opsonin Pharma Limited Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.00, 115.00, 215.00 MRP
Sidobac 1gm Incepta Pharmaceuticals Limited Ceftazidime USP 1gm (as a mixture of Ceftazidime pentahydrate and Sodium Carbonate) IV/IM Injection 1x1's:MRP 215 Tk
Sidobac 250 Incepta Pharmaceuticals Limited Ceftazidime USP 250 mg (as a mixture of Ceftazidime pentahydrate and Sodium Carbonate) IV/IM Injection 1x1's:MRP 70 Tk
Sidobac 500 Incepta Pharmaceuticals Limited Ceftazidime USP 500 mg (as a mixture of Ceftazidime pentahydrate and Sodium Carbonate) IV/IM Injection 1x1's:MRP 115 Tk
TAZID 1G Square Pharmaceuticals Ltd. Ceftazidime 1 gm IM/IV Injection 1x1's: 240.72 MRP
TAZID 250 Square Pharmaceuticals Ltd. Ceftazidime 250mg IM/IV Injection 1x1's: 85.26 MRP
TAZID 500 Square Pharmaceuticals Ltd. Ceftazidime 500mg IM/IV Injection 1x1's: 130.39 MRP
TIZIME Globe Pharmaceuticals Ltd Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.00, 115.00, 215.00 MRP
TRIZIDIM The Acme Laboratories Ltd. Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.26, 115.43, 215.80 MRP
TRUM 3 Drug International Ltd Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.00, 120.00, 225.00 MRP
ZIDICEF Popular Pharmaceuticals Ltd. Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.26, 115.43, 215.81 MRP
ZIDIM Orion Pharma Ltd. Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.26, 115.43, 215.81 MRP
ZIDIMAX Biopharma Laboratories Ltd Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.00, 115.00, 225.00 MRP
ZITUM ACI Ltd. Ceftazidime pentahydrate 250mg, 500mg & 1gm (IV/IM) Injection 250mg, 500mg & 1gm: 70.26, 115.43, 225.85 MRP

Gen. MedInfo

Why is this medication prescribed?

Ceftazidime eliminates bacteria that cause many kinds of infections, including lung, skin, bone, joint, stomach, blood, gynecological, and urinary tract infections.This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information. The drug will be either injected into a large muscle (such as your buttock or hip) or added to an intravenous fluid that will drip through a needle or catheter placed in your vein for 30 minutes, one to three times a day.

Your health care provider (e.g. doctor) may measure the effectiveness and side effects of your treatment using laboratory tests and physical examinations. It is important to keep all appointments with your doctor and the laboratory. The length of treatment depends on how your infection and symptoms respond to the medication.

Precautions

Before administering ceftazidime 

  • tell your doctor if you are allergic to ceftazidime, any other cephalosporin [e.g., cefaclor, cefadroxil, or cephalexin], penicillins, or any other drugs.
  • tell your doctor what prescription and nonprescription medications you are taking, especially other antibiotics, probenecid, and vitamins.
  • tell your doctor if you have or have ever had kidney, liver, or gastrointestinal disease (especially colitis).
  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking ceftazidime, call your doctor.
  • if you have diabetes and regularly check your urine for sugar, use Clinistix or TesTape. Do not use Clinitest tablets because ceftazidime may cause false positive results.

Administering your medication 

Before you administer ceftazidime, look at the solution closely. It should be clear and free of floating material. Gently squeeze the bag or observe the solution container to make sure there are no leaks. Do not use the solution if it is discolored, if it contains particles, or if the bag or container leaks. Use a new solution, but show the damaged one to your health care provider.

It is important that you use your medication exactly as directed. Do not stop your therapy on your own for any reason because your infection could worsen and result in hospitalization. Do not change your dosing schedule without talking to your health care provider. Your health care provider may tell you to stop your infusion if you have a mechanical problem (such as a blockage in the tubing, needle, or catheter); if you have to stop an infusion, call your health care provider immediately so your therapy can continue.

Side effects

Ceftazidime may cause side effects. If you are administering ceftazidime into a muscle, it may be mixed with lidocaine (Xylocaine) to reduce pain at the injection site. Tell your health care provider if any of these symptoms are severe or do not go away: 
  • diarrhea

  • stomach pain

  • upset stomach

  • vomiting

 If you experience any of the following symptoms, call your health care provider immediately:

  • unusual bleeding or bruising

  • difficulty breathing

  • itching

  • rash

  • hives

  • sore mouth or throat

Storing your medication 

  •  Your health care provider probably will give you a several-day supply of ceftazidime at a time. If you are receiving ceftazidime intravenously (in your vein), you probably will be told to store it in the refrigerator or freezer.
  • Take your next dose from the refrigerator 1 hour before using it; place it in a clean, dry area to allow it to warm to room temperature.

  • If you are told to store additional ceftazidime in the freezer, always move a 24-hour supply to the refrigerator for the next day's use.

  • Do not refreeze medications.

 If you are receiving ceftazidime intramuscularly (in your muscle), your health care provider will tell you how to store it properly.

Store your medication only as directed. Make sure you understand what you need to store your medication properly.

Keep your supplies in a clean, dry place when you are not using them, and keep all medications and supplies out of reach of children. Your health care provider will tell you how to throw away used needles, syringes, tubing, and containers to avoid accidental injury.

In case of emergency/overdose 

In case of overdose, consult your doctor. If the victim has collapsed or is not breathing, consult local medical emergency services.

Signs of infection

If you are receiving ceftazidime in your vein or under your skin, you need to know the symptoms of a catheter-related infection (an infection where the needle enters your vein or skin). If you experience any of these effects near your intravenous catheter, tell your health care provider as soon as possible: 
  • tenderness

  • warmth

  • irritation

  • n

    drainage

  • redness

  • swelling

  • pain

What other information should I know?

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your response to this medicine.

Do not let anyone else use your medication. If you still have symptoms and need further treatment, consult your doctor.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Ref:  U.S. National Library of Medicine.


This information is provided for reference only and not a replacement for and should only be used in conjunction with full consultation with a registered medical practitioner. It may not contain all the available information you require and cannot substitute professional medical care, nor does it take into account all individual circumstances. Although great effort has been made to ensure content accuracy, mph-bd shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise.